Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$17.41 USD
+0.28 (1.63%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $17.40 -0.01 (-0.06%) 4:26 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 35% (88 out of 250)Zacks Sector Rank
Top 50% (8 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.17 | 1.35 | 9.99 |
Current Quarter Estimate | -0.36 | 7.43 | 57.00 |
Year Ago Quarter Estimate | -0.34 | 0.12 | 52.54 |
Next Quarter Estimate | -0.37 | 7.81 | 61.00 |
Next Year Estimate | -1.98 | 37.76 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | -1.27 | 15.50 | 15.67 |
Next Year | -24.53 | 8.80 | 9.31 |
Last 5 Years | NA | 1.00 | 8.10 |
Next 5 Years | NA | 20.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -2.18 |
Price/Book (MRQ) | 2.98 | 2.20 |
Price/Cash Flow (MRFY) | NA | 16.72 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | NA | -167.94% |
Return on Equity (TTM) | -29.09% | -59.04% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.